References:
1. Sia
D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin,
Molecular Class, and Effects on Patient Prognosis. GASTROENTEROLOGY
2017;152(4):745-61.
2.
Bray
F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018;68(6):394-424.
3.
Jiang
Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression
and immunotherapy. World J Gastroenterol 2019;25(25):3151-67.
4. Kim
DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond
sorafenib-chemotherapy. J Gastrointest Oncol 2017;8(2):256-65.
5. Hou
J, Zhang H, Sun B, Karin M. The Immunobiology of Hepatocellular
Carcinoma in Humans and Mice: Basic Concepts and Therapeutic
Implications. J HEPATOL 2019.
6.
Gajewski
TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor
microenvironment. NAT IMMUNOL 2013;14(10):1014-22.
7.
Makarova-Rusher
OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion
and immune activation in HCC. J HEPATOL 2015;62(6):1420-9.
8.
Chaturvedi
V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human
regulatory T cells require IL-35 to mediate suppression and infectious
tolerance. J IMMUNOL 2011;186(12):6661-6.
9. Xue
W, Yan D, Kan Q. Interleukin-35 as an Emerging Player in Tumor
Microenvironment. J CANCER 2019;10(9):2074-82.
10. Fu
YP, Yi Y, Cai XY, et al. . Overexpression of interleukin-35
associates with hepatocellular carcinoma aggressiveness and recurrence
after curative resection. Br J Cancer 2016;114(7):767-76.
11.
Zhang
MX, Gan W, Jing CY, et al. . Overexpression of interleukin-35 in
intrahepatic cholangiocarcinoma is a prognostic indicator after curative
resection. CANCER SCI 2018;109(4):1195-206.
12.
Wei X,
Zhang J, Gu Q, Huang M, Zhang W, Guo J, Zhou X. Reciprocal Expression of
IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are
Required for Maintenance of Immune Tolerance. CELL REP
2017;21(7):1853-69.
13.
Sawant
DV, Yano H, Chikina M, et al. . Adaptive plasticity of IL-10(+)
and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion.
NAT IMMUNOL 2019;20(6):724-35.
14.
Shi
YY, Dai MJ, Wu GP, Zhou PP, Fang Y, Yan XB. Levels of interleukin-35 and
its relationship with regulatory T-cells in chronic hepatitis B
patients. VIRAL IMMUNOL 2015;28(2):93-100.
15.
Luo M,
Peng H, Chen P, Zhou Y. The immunomodulatory role of interleukin-35 in
fibrotic diseases. Expert Rev Clin Immunol 2019;15(4):431-9.
16.
Shi M,
Wei J, Dong J, Meng W, Ma J, Wang T, Wang N, Wang Y. Function of
interleukin-17 and -35 in the blood of patients with hepatitis B-related
liver cirrhosis. MOL MED REP 2015;11(1):121-6.
17.
Zheng
XF, Hu XY, Ma B, et al. . Interleukin-35 Attenuates
D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing
Interleukin-10 Production in Kupffer Cells. FRONT PHARMACOL 2018;9:959.
18.
Wang
W, Guo H, Li H, Yan Y, Wu C, Wang X, He X, Zhao N. Interleukin-35
Gene-Modified Mesenchymal Stem Cells Protect Concanavalin A-Induced
Fulminant Hepatitis by Decreasing the Interferon Gamma Level. HUM GENE
THER 2018;29(2):234-41.
19.
Trehanpati
N, Vyas AK. Immune Regulation by T Regulatory Cells in Hepatitis B
Virus-Related Inflammation and Cancer. SCAND J IMMUNOL
2017;85(3):175-81.
20.
Zhao
N, Li H, Yan Y, Jiang R, He X. Mesenchymal stem cells overexpressing
IL-35 effectively inhibit CD4(+) T cell function. CELL IMMUNOL
2017;312:61-6.
21.
Yang
L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 Dampens CD8(+) T Cells
Activity in Patients With Non-viral Hepatitis-Related Hepatocellular
Carcinoma. FRONT IMMUNOL 2019;10:1032.
22.
Rooney
MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic
properties of tumors associated with local immune cytolytic activity.
CELL 2015;160(1-2):48-61.